Home/Pipeline/Oncolytic Virus Therapy (undisclosed)

Oncolytic Virus Therapy (undisclosed)

Advanced Solid Tumors

PreclinicalCandidate Selection

Key Facts

Indication

Advanced Solid Tumors

Phase

Preclinical

Status

Candidate Selection

Company

A Japanese biotech developing next-generation vaccinia virus-based oncolytic immunotherapies to eradicate cancer.

Drug	Company	Phase	Status
NT219	Purple Biotech	Phase 1/2	Active
INDP-101	Indaptus Therapeutics	Phase 1	Active, not recruiting
NST-101 (estimated)	Novastage Pharmaceuticals	Phase 1/2	Active
Meta10-TILs	Leman Biotech	Phase 1	Active (Investigator-Initiated Trial)
PM14	PharmaMar	Phase 1/2	Active
Ecubectedin (PM54)	PharmaMar	Phase 1	Active
M8891	Merck KGaA	Phase 1/2	Active
P-002	Panacea Biotec	Phase 1/2	Active
Undisclosed kinase inhibitor	Tyligand Bioscience	Phase 1	Active
TYK-001	TYK Medicines	Phase 1/2	Active
PT-112	SciClone Pharmaceuticals	Phase 1	Active - Subject Recruitment
AP-202	Advance Pharmaceutical	Phase 1/2	Active, dose expansion